Literature DB >> 3002605

The effect of RU 41.740 (Biostim) on the production of interleukin-1 by monocytes and enriched large granular lymphocytes in normals and patients with hepatocellular carcinoma.

J Herman, M C Kew, A R Rabson.   

Abstract

The effect of RU 41.740 on natural killer (NK) cell cytotoxicity from normals and patients with advanced hepatocellular carcinoma (HCC) was studied. RU 41.740-treated normal enriched large granular lymphocytes (LGLs) showed increased cytotoxic activity against 51Cr-labelled K562 cells. Although the drug increased the cytotoxic activity of LGLs from HCC patients, these results were not statistically significant. As LGLs have been shown to release interleukin-1 (IL-1) after suitable stimulation the effects of RU 41.740 on production of this cytokine from both monocytes and LGLs was studied. The drug stimulated IL-1 release from normal cells but monocyte and LGL IL-1 production from HCC patients was not influenced by RU 41.740 by RU 41.740. It is concluded, therefore, that although RU 41.740 can stimulate natural cytotoxicity and IL-1 production by normal LGLs, it is unable to correct the defect which exists in these functions in patients with large mass tumours.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3002605     DOI: 10.1007/bf00199373

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  22 in total

1.  Mechanism of action of human B cell-activating factor. I. Comparison of the plaque-stimulating activity with thymocyte-stimulating activity.

Authors:  D D Wood
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

2.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

3.  [Double-blind study of an immunomodulator of bacterial origin (Biostim) in the prevention of infectious episodes in chronic bronchitis].

Authors:  J R Viallat; D Costantini; C Boutin; P Farisse
Journal:  Poumon Coeur       Date:  1983 Jan-Feb

4.  A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells.

Authors:  M J Droller; M U Schneider; P Perlmann
Journal:  Cell Immunol       Date:  1978-08       Impact factor: 4.868

5.  The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity.

Authors:  R A Dempsey; C A Dinarello; J W Mier; L J Rosenwasser; M Allegretta; T E Brown; D R Parkinson
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

6.  Purification and properties of human B cell-activating factor.

Authors:  D D Wood
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

7.  Defective natural cytotoxicity in patients with cancer: normal number of effector cells but decreased recycling capacity in patients with advanced disease.

Authors:  E H Steinhauer; A T Doyle; J Reed; A S Kadish
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

8.  The effects of interleukin 1 on human B cell activation and proliferation.

Authors:  R J Falkoff; A Muraguchi; J X Hong; J L Butler; C A Dinarello; A S Fauci
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

9.  Depressed natural killer cell activity in patients with hepatocellular carcinoma. In vitro effects of interferon and levamisole.

Authors:  K Son; M Kew; A R Rabson
Journal:  Cancer       Date:  1982-12-15       Impact factor: 6.860

10.  The functional relationship of the interleukins.

Authors:  K A Smith; L B Lachman; J J Oppenheim; M F Favata
Journal:  J Exp Med       Date:  1980-06-01       Impact factor: 14.307

View more
  1 in total

1.  Direct activation of human monocyte-derived macrophages by a bacterial glycoprotein extract inhibits the intracellular multiplication of virulent Legionella pneumophila serogroup 1.

Authors:  P Rajagopalan; E Dournon; J L Vildé; J J Pocidalo
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.